Medivir Q1 2024: Another TTP Improvement - Redeye

Redeye reviews Medivir's fourth quarter report, which presented another improvement of median time to progression for fostrox, now at 7 months. The way forward with the planned phase IIb study has also been updated after a type C meeting with the FDA.

Länk till analysen i sin helhet: https://www.redeye.se/research/1001240/medivir-q1-2024-another-ttp-improvement?utm_source=finwire&utm_medium=RSS